Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT 3 ‐ ITD acute myeloid leukaemia in first complete remission

Open access
Brunner, Andrew M., Li, Shuli, Fathi, Amir T., Wadleigh, Martha, Ho, Vincent T., Collier, Kerry, Connolly, Christine, Ballen, Karen K., Cutler, Corey S., Dey, Bimalangshu R., El‐Jawahri, Areej, Nikiforow, Sarah, McAfee, Steven L., Koreth, John, Deangelo, Daniel J., Alyea, Edwin P., Antin, Joseph H., Spitzer, Thomas R., Stone, Richard M., Soiffer, Robert J., Chen, Yi‐Bin·2016·British Journal of Haematology

Abstract

Summary: We performed a retrospective study analysing the effect of sorafenib, an oral fms‐Like Tyrosine Kinase 3 ( FLT 3)/multikinase inhibitor, as post‐transplant maintenance in adult patients with FLT 3 ‐internal tandem duplication ( ITD ) acute myeloid leukaemia ( AML ). We identified consecutive patients with FLT 3‐ ITD AML diagnosed between 2008 and 2014 who received haematopoietic cell transplantation ( HCT ) in first complete remission ( CR 1). Post‐ HCT initiation of sorafenib (yes/no) was evaluated as a time‐varying covariate in the overall survival/progression‐free survival ( OS / PFS ) analysis and we performed a landmark analysis of controls alive without relapse at the median date of sorafenib initiation. We identified 26 sorafenib patients and 55 controls. Median follow‐up was 27·2 months post‐ HCT for sorafenib survivors, and 38·4 months for controls ( P = 0·021). The median time to initiating sorafenib was 68 days post‐ HCT ; 43 controls were alive without relapse at this cut‐off. Sorafenib patients had improved 2‐year OS in the d+68 landmark analysis (81% vs. 62%, P = 0·029). Sorafenib was associated with improved 2‐year PFS (82% vs. 53%, P = 0·0081) and lower 2‐year cumulative incidence of relapse (8·2% vs. 37·7%, P = 0·0077). In multivariate analysis, sorafenib significantly improved OS [Hazard ratio ( HR ) 0·26, P = 0·021] and PFS ( HR 0·25, P = 0·016). There was no difference in 2‐year non‐relapse mortality (9·8% vs. 9·3%, P = 0·82) or 1‐year chronic graft‐versus‐host disease (55·5% vs. 37·2%, P = 0·28). These findings suggest potential benefit of post‐ HCT sorafenib in FLT 3 ‐ ITD AML , and support further evaluation of post‐ HCT FLT 3 inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.14260

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Brunner, A. M., Li, S., Fathi, A. T., Wadleigh, M., Ho, V. T., Collier, K., Connolly, C., Ballen, K. K., Cutler, C. S., Dey, B. R., El‐Jawahri, A., Nikiforow, S., McAfee, S. L., Koreth, J., Deangelo, D. J., Alyea, E. P., Antin, J. H., Spitzer, T. R., Stone, R. M., Soiffer, R. J., & Chen, Y.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2016-07-19
Volume
175
Issue
3
Pages
496-504
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2502940040
Cited by
174
References
1
FWCI
22.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT 3 ‐ ITD acute myeloid leukaemia in first complete remission. https://app.cochat.ai/papers/10.1111/bjh.14260
The paper
Brunner, A. M., Li, S., Fathi, A. T., Wadleigh, M., Ho, V. T., Collier, K., Connolly, C., Ballen, K. K., Cutler, C. S., Dey, B. R., El‐Jawahri, A., Nikiforow, S., McAfee, S. L., Koreth, J., Deangelo, D. J., Alyea, E. P., Antin, J. H., Spitzer, T. R., Stone, R. M., . . . Chen, Y. (2016). Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT 3 ‐ ITD acute myeloid leukaemia in first complete remission. British Journal of Haematology. https://doi.org/10.1111/bjh.14260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.